A Phase 2, Randomized, Double Blind, Placebo Controlled, Paralel Group, Multiple Center Study to Evaluate the Safety, Tolerability, and Efficacy of NGM282 Administered for 12 Weeks in Patients with Histoloically Confirmed Nonalcoholic Steatohepatitis(NAS

Project: Research project

Project Details

StatusFinished
Effective start/end date5/20/155/20/18

Funding

  • NGM Biopharmaceuticals, Inc. (Protocol 15-0105)